6 days ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Alkermes (ALKS – Research Report).
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie (ABBV)
Leerink Partners analyst David Risinger maintained a Buy rating on AbbVie on July 10. The company's shares closed last Monday at $191.52.
According to Risinger is a 5-star analyst with an average return of 9.1% and a 54.3% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals. ;'>
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.00, implying a 10.6% upside from current levels. In a report issued on June 30, William Blair also maintained a Buy rating on the stock.
Alkermes (ALKS)
Leerink Partners analyst Marc Goodman maintained a Hold rating on Alkermes on July 11. The company's shares closed last Monday at $29.69.
According to Goodman is a 4-star analyst with an average return of 4.5% and a 47.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, ACADIA Pharmaceuticals, and Avadel Pharmaceuticals. ;'>
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $40.00, representing a 32.5% upside. In a report issued on July 7, RBC Capital also maintained a Hold rating on the stock with a $40.00 price target.
